Alpha-Lipoic Acid

The diabetic neuropathy evidence for ALA is among the strongest evidence bases for any supplement. Multiple randomized controlled trials — ALADIN (PMID 7589950), ALADIN III (PMID 10391387), SYDNEY 2 (PMID 17140036), and the four-year NATHAN 1 (PMID 21953615) — consistently demonstrate that 600 mg/day of oral ALA meaningfully reduces neuropathic symptoms (pain, burning, paresthesias, numbness) and improves nerve conduction in type 1 and type 2 diabetics. The effect sizes are clinically meaningful and comparable to pharmaceutical options like duloxetine or pregabalin. Germany has licensed ALA at 600 mg/day as a prescription medication for diabetic polyneuropathy since the 1960s based on this evidence. Expected timeline: symptom improvement over 3-5 weeks of oral therapy, with greater improvements if started with IV loading at a functional medicine clinic. This is one of the few supplements where the evidence base rivals or exceeds pharmaceutical alternatives, and where clinical practice in one major country has formally recognized the benefit.

R-ALA is biologically superior — it''s the natural enantiomer used by human enzymes, while the synthetic S-ALA in racemic mixtures is poorly metabolized and may even competitively inhibit R-ALA pharmacology. Pharmacokinetic studies (Hermann PMID 17024766) show R-ALA has approximately 40% higher peak plasma concentrations and 2-3x higher AUC than racemic at equivalent total doses. In practice, 300 mg R-ALA approximates 600 mg racemic. Whether this is worth the roughly 2-3x price premium depends on context. For general antioxidant support, racemic at higher doses is fine and cost-effective. For clinical indications (diabetic neuropathy, insulin resistance) where the trial evidence used racemic, matching the trial dose (600 mg racemic) is reasonable. For users with GI intolerance to high-dose racemic, R-ALA at lower doses achieves the same effects with less GI burden. Stabilized sodium R-lipoate (Na-R-ALA) further improves bioavailability and is worth the premium for serious users. Beware that some products marketed as "R-ALA" are racemic — purchase from reputable suppliers with third-party verification.

The weight-loss effect of ALA is real but modest. Meta-analyses (Namazi PMID 28456476; Kucukgoncu PMID 27702795) found that ALA at 600-1800 mg/day produces approximately 1-2 kg additional weight loss over placebo during 8-20 week trials. The mechanism involves AMPK activation in the hypothalamus (reduced appetite) and peripheral tissues (enhanced fatty acid oxidation), plus improved insulin sensitivity. This is a meaningful but small effect — ALA is not a primary weight-loss intervention, comparable perhaps to modest dietary changes rather than medications like GLP-1 agonists. ALA may be a reasonable adjunct for users pursuing comprehensive lifestyle-based weight management, particularly those with insulin resistance or metabolic syndrome where ALA''s other benefits compound. Do not expect dramatic results from ALA monotherapy for obesity.

Yes, if you''re diabetic on insulin, sulfonylureas, or meglitinides. ALA''s insulin-sensitizing effects can precipitate symptomatic hypoglycemia, particularly during the first 2-4 weeks of initiation or dose increase. Check blood glucose more frequently during this window, and anticipate that insulin or sulfonylurea doses may need reduction (often 10-20%). Discuss ALA with your prescribing clinician before starting if on these medications. For diabetics on metformin alone, hypoglycemia risk is low because metformin itself rarely causes hypoglycemia. For non-diabetics, clinically significant hypoglycemia from ALA is uncommon but has been reported, especially with high doses on empty stomach combined with low-carbohydrate eating or fasting. If you experience symptoms of hypoglycemia (shakiness, sweating, confusion, palpitations) after ALA, check blood glucose if possible and eat some carbohydrate. Persistent issues warrant reducing ALA dose or discontinuation.

Empty stomach — 30-60 minutes before a meal or 2 hours after — produces approximately 30-50% higher plasma concentrations than taking with food, particularly carbohydrate-rich meals. Take your ALA in the morning fasted, or pre-workout, or well before lunch. If empty stomach causes GI upset (nausea, heartburn), a small amount of protein (e.g., a handful of nuts, a small piece of cheese) represents a reasonable compromise that preserves most of the absorption advantage. Avoid taking with large mixed meals. Some commercial products use time-release technology or liposomal delivery to reduce GI irritation, but this may also reduce peak plasma exposure and thus reduce insulin-sensitivity effects — simple immediate-release with empty-stomach dosing is the best balance for most users. If you''re on levothyroxine for thyroid, take it morning fasted and separate your ALA by at least 4 hours (typically ALA with lunch or late afternoon).

Yes, generally. The longest controlled safety data comes from NATHAN 1, a 4-year trial of 600 mg/day in diabetic polyneuropathy patients with no major safety signals (PMID 21953615). German clinical practice has used 300-600 mg/day for neuropathy for decades without emerging safety concerns. Chronic use at standard doses (300-600 mg/day) appears very safe. The main considerations for long-term users are: (1) biotin replacement — chronic high-dose ALA competes with biotin absorption at the SMVT transporter, producing functional biotin deficiency over months; add biotin 2-5 mg/day to prevent this; (2) occasional monitoring of liver enzymes, glucose, and thyroid function if on chronic high-dose; (3) awareness of insulin autoimmune syndrome risk in Asian populations; (4) appropriate adjustments for concurrent diabetes medications. At standard doses with these precautions, ALA is among the safer supplements for indefinite use. Very high doses (≥1800 mg/day) for extended periods have less long-term data and should be reserved for specific indications with medical oversight.

Biochemically, yes — dihydrolipoic acid (DHLA, the reduced form of ALA) has two thiol groups in an orientation that forms stable complexes with mercury, arsenic, lead, and cadmium, and ALA''s small size allows intracellular and CNS penetration that larger chelators like DMSA can''t achieve. Whether it works clinically depends heavily on the protocol. The Andrew Cutler protocols specify dosing every 3-4 hours around the clock during active "rounds" because ALA''s short half-life (30-60 minutes) means that single or twice-daily dosing can mobilize mercury from tissues faster than the body excretes it, potentially causing redistribution to sensitive tissues including the brain. For documented heavy metal toxicity, mainstream occupational and toxicology medicine still prefers DMSA or DMPS as first-line chelators — they have more controlled clinical trial evidence and simpler dosing. ALA has a legitimate role in integrative chelation protocols but should be pursued with a clinician experienced in heavy metal therapy, not as a DIY project. For users concerned about mercury from dental amalgams or fish consumption without documented toxicity, ALA''s general antioxidant support is reasonable and low-risk, while aggressive chelation protocols require careful consideration and supervision.

This is a genuinely unresolved question. The theoretical concern is that antioxidants may reduce the efficacy of chemotherapy agents (cisplatin, carboplatin, doxorubicin, taxanes) and radiation therapy that work through oxidative damage to cancer cells. Clinical evidence is mixed — some studies suggest ALA selectively protects healthy tissue (reducing chemotherapy-induced peripheral neuropathy) without impairing tumor response, while others raise concerns about reduced treatment efficacy. The safe default for patients on active chemotherapy or radiation is to avoid ALA and other high-dose antioxidants during treatment cycles, or to discuss with the treating oncologist before starting. Post-treatment use for established chemotherapy-induced peripheral neuropathy is much better supported and lower-risk. If your oncologist is unfamiliar with ALA specifically, asking them to review the mixed literature on antioxidants during chemotherapy is reasonable — the answer often depends on the specific drug, cancer type, and treatment goals.

Yes, to a modest degree. Meta-analyses show that ALA 600-1800 mg/day produces measurable but modest improvements in HOMA-IR (insulin resistance index), fasting glucose, HbA1c, and triglycerides in metabolic syndrome and pre-diabetes (Akbari PMID 29361170). Effect sizes are smaller than metformin or GLP-1 agonists but real. For non-diabetics pursuing metabolic optimization, ALA is a reasonable component of a comprehensive approach that also emphasizes exercise, diet, weight management, magnesium, and other insulin-supportive nutrients. Expect modest improvements in HOMA-IR over 3-6 months. If pre-diabetic with significant insulin resistance, consider combining ALA with berberine 500 mg 2-3x daily and metformin if prescribed by your clinician for additive AMPK activation. Don''t expect ALA alone to resolve serious metabolic dysfunction without concurrent lifestyle intervention.

Because ALA and biotin share the same intestinal uptake transporter (sodium-dependent multivitamin transporter, SMVT) and have similar structural features. At doses ≥600 mg/day for more than a few months, ALA competitively inhibits biotin absorption and can induce functional biotin deficiency (Zempleni PMID 19348577). Biotin is required for four critical carboxylase enzymes in fatty acid, branched-chain amino acid, and odd-chain fatty acid metabolism, and deficiency symptoms include hair thinning, brittle nails, dermatitis, muscle pain, and in severe cases neurological effects. The solution is simple and cheap: add biotin 2-5 mg/day when taking chronic ALA ≥600 mg/day. Many commercial ALA products include biotin for this reason — check the label. Note that high-dose biotin can interfere with several laboratory immunoassays (thyroid function, cardiac troponin, hormone tests), so pause biotin for 48-72 hours before testing if your labs will be affected. For chronic ALA users not taking biotin, look for subtle signs of deficiency (hair and nail changes, skin issues) and add biotin empirically if they appear.